ArticleAfrican journal of primary health care & family medicine2018
A mortality review of tuberculosis and HIV co-infected patients in Mahalapye, Botswana: Does cotrimoxazole preventive therapy and/or antiretroviral therapy protect against death?
Article in African journal of primary health care & family medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Risk factors and mortality rates for children co-infected with HIV and TB in Ethiopia: a systematic review and meta-analysis.International health · 2026Pooled it
- Meta-analysis of TB & HIV co-infection mortality rate in sub-Saharan African children, youth, and adolescents.Italian journal of pediatrics · 2025Pooled it
- Mortality and associated factors among patients with TB-HIV co-infection in Ethiopia: a systematic review and meta-analysis.BMC infectious diseases · 2024Pooled it
- Burden of mortality and its predictors among TB-HIV co-infected patients in Ethiopia: Systematic review and meta-analysis.PloS one · 2024Pooled it
- Trial
- Tertiary-care management of TB/HIV co-infection in Port Harcourt, Nigeria: A retrospective cohort analysis.PloS one · 2026Article
- Bacterial co-occurrence with pulmonary TB, a respiratory tract infection (RTI): A cross-sectional study in a resource-limited setting.Journal of clinical tuberculosis and other mycobacterial diseases · 2025Article
- Tuberculosis treatment outcome of TB/HIV co-infected patients at Adare Hospital, Hawassa City Administration, Sidama Region.BMC infectious diseases · 2024Article
- Pediatric tuberculosis outcomes and factors associated with unfavorable treatment outcomes in Botswana, 2008-2019: a retrospective analysis.BMC public health · 2022Article
- Predictors of All-Cause Mortality Among People With Human Immunodeficiency Virus (HIV) in a Prospective Cohort Study in East Africa and Nigeria.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Outcomes and predictors of tuberculosis mortality in Kweneng West District, Botswana: a retrospective cohort study.The Pan African medical journal · 2022Article
- Dual Nature of Relationship between Mycobacteria and Cancer.International journal of molecular sciences · 2021Review
- Retention in Care among Patients Attending a Large HIV Clinic in Nigeria Who Were Treated for Tuberculosis.Journal of the International Association of Providers of AIDS CareArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe World Health Organization aims to reduce tuberculosis (TB) mortality rate from 15% in 2015 to 6.5% by 2025.
aimThis study determined the profile of TB and human immunodeficiency virus (HIV) co-infected patients who died in Mahalapye District, Botswana, while on anti-TB medication and the factors that contributed to such outcome.
settingThe study was conducted in the Mahalapye Health District in Botswana.
methodsThis was a cross-sectional study that reviewed patient records from the Mahalapye District Health Management Team Electronic Tuberculosis Register from January 2013 to December 2015.
resultsThe majority of the TB and HIV co-infected patients were on antiretroviral therapy (ART) (486 [81.63%]) or were initiated cotrimoxazole preventive therapy (CPT) (518 [87.2%]) while taking anti-TB treatment. Seventy-three (13.6%) TB and HIV co-infected patients died before completing anti-TB treatment. Three-quarters (54 [74.4%]) of patients who died before completing anti-TB treatment were on ART, among them two patients who were on ART at least 3 months prior to commencing anti-TB. Also, the majority (64 [87.7%]) of TB and HIV co-infected patients were commenced on CPT prior to death. There was a bimodal density curve of death occurrence in those who did not commence ART and in those who did not commence CPT.
conclusionThis study established that TB and HIV co-infected patients had a TB mortality of 13.6%. A high mortality rate was observed during the first 3 months in those who did not take ART and during the second and the fifth month in those who did not commence CPT. Further study is needed to clarify this matter.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.